Cancer stem cells: Are we missing the target?

Journal of the National Cancer Institute

Volumn 96, Issue 8, 2004, Pages 583-585

  Jones, Richard J ^a,b   Matsui, William H ^a   Smith, B Douglas ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Bunting Blaustein Cancer   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CD19 ANTIGEN; CD33 ANTIGEN; CYTARABINE; GEMTUZUMAB OZOGAMICIN; HYBRID PROTEIN; IMATINIB; INTERFERON; PROTEIN TYROSINE KINASE; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CELL; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DISEASE CONTROL; DRUG APPROVAL; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE TRANSFER; HUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SIDE EFFECT; SIGNAL TRANSDUCTION; STEM CELL; TARGET CELL; ANIMAL; CANCER STEM CELL; DRUG DESIGN; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; NEOPLASM; REVIEW; SURVIVAL;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; NEOPLASMS; PIPERAZINES; PYRIMIDINES; SURVIVAL; TUMOR STEM CELLS;

EID: 2342535230     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh095     Document Type: Article

References (31)

1. Ben-Neriah Y, Daley GQ, Mes-Masson A-M, Witte ON, Baltimore D. The chronic myelogenous leukemia - specific P210 protein is the product of the bcr-abl hybrid gene. Science 1986;233:212-4.
2. bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
3. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
4. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
5. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
6. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
7. Chronic Myelogenous Leukemia Clinical Practice Guidelines in Oncology. J Natl Comprehensive Cancer Network 2003;1:482-500.
8. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98:3074-81.
9. Mauro MJ, Druker BJ, Kuyl J, Kurilik G, Maziarz RT. Increasing levels of detectable leukemia in imatinib treated CML patients with previously undetectable or very low levels of BCR-ABL. Proc ASCO 2003;22:569.
10. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
11. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-6.
12. Bedi A, Zehnbauer BA, Collector MI, Barber JP, Zicha MS, Sharkis SJ, et al. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 1993;81:2898-902.
13. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-25.
14. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002;99:3792-800.
15. Raaijmakers MH, van Emst L, De Witte T, Mensink E, Raymakers RA. Quantitative assessment of gene expression in highly purified hematopoietic cells using real-time reverse transcriptase polymerase chain reaction. Exp Hematol 2002;30:481-7.
16. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368-73.
17. Jones RJ. Leukemic stem cells: where have they gone wrong? Blood 2001;97:3681-2.
18. Pierce A, Smith DL, Jakobsen LV, Whetton AD, Spooncer E. The specific enhancement of interferon alpha induced growth inhibition by BCR/ABL only occurs in multipotent cells. Hematol J 2001;2:257-64.
19. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang TC-CJ, Minden M, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8.
20. George AA, Franklin J, Kerkof K, Shah AJ, Price M, Tsark E, et al. Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia. Blood 2001;97:3925-30.
21. Nilsson L, Astrand-Grundstrom I, Anderson K, Arvidsson I, Hokland P, Bryder D, et al. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 2002;100:259-67.
22. Al Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-8.
23. Matsui WH, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103:2332-6.
24. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
25. Wittebol S, Raymakers R, van de LL, Mensink E, De Witte T. In AML t(8;21) colony growth of both leukemic and residual normal progenitors is restricted to the CD34+, lineage-negative fraction. Leukemia 1998;12: 1782-8.
26. Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-. Blood 1998;92:4325-35.
27. Uckun FM, Messinger Y, Chen CL, O'Neill K, Myers DE, Goldman F, et al. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin Cancer Res 1999;5:3906-13.
28. Szatrowski TP, Dodge RK, Reynolds C, Westbrook CA, Frankel SR, Sklar J, et al. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer 2003;97: 1471-80.
29. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
30. Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002;25:72-81.
31. Pilarski LM, Jensen GS. Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am 1992;6:297-322.